| 祁巧玲,闵旭红,张泉,等.2020—2022年国家医保谈判新型抗肿瘤药物在某三甲胸科医院应用分析[J].安徽医药,2024,28(9):1895-1901. |
| 2020—2022年国家医保谈判新型抗肿瘤药物在某三甲胸科医院应用分析 |
| Application of new antineoplastic drugs priced by medical insurance price negotiation in a tertiary chest hospital from 2020 to 2022 |
| |
| DOI：10.3969/j.issn.1009-6469.2024.09.043 |
| 中文关键词: 抗肿瘤药 国家医疗保险 目录，药物 费用，药物 国家医保谈判药物 使用情况 合理用药 质控指标 |
| 英文关键词: Antineoplastics National medical insurance Catalogs, drug Fees, pharmaceutical National negotiation drugs Usage situation Rational utilization of drugs Quality control indexes |
| 基金项目:安徽省卫生健康委科研项目( AHWJ2021b149) |
|
| 摘要点击次数: 667 |
| 全文下载次数: 347 |
| 中文摘要: |
| 目的分析某三甲胸科医院国家医保谈判新型抗肿瘤药物的临床应用情况，为规范其合理利用及后续政策优化提供参考依据。方法对 2020年 3月至 2023年 2月安徽省胸科医院国家医保谈判新型抗肿瘤药物销售金额、用药频度(DDDs)、日均费用(DDC)、金额排序 /DDDs排序比(B/A)、临床用药合理性以及抗肿瘤药物质控指标等进行统计分析。结果 2020—2022年国家医保谈判的新型抗肿瘤药物销售金额占药品总金额比例 3年依次为 12.55%、16.33%、15.84%，其中大分子单克隆抗体金额占比逐年递增，依次为: 3.28%、5.52%、6.76%。总 DDDs 2021年度较 2020年度增长 72.24%，2022年度较 2021年度增长 26.26%。2020年谈判新增的药物 DDDs增长幅度特别大，其中替雷利珠单抗(17 162.50%)增幅最大。 DDC逐年降低的药物占比为 63.16%，每年 B/A≥1的药物占 65.00%以上。大分子单克隆抗体国产药物 DDDs占比越来越高。新型抗肿瘤药物合理率逐年提升，不良反应例数近两年均在 50例以上，拓展性临床应用较少， 3年使用抗肿瘤药物病人的病理诊断和检测率均为 100.00%，限制使用级抗肿瘤药物使用率逐年增长。结论该医院国家医保谈判新型抗肿瘤药物使用基本合理， DDDs明显增加， DDC降低，且国产大分子单克隆抗体使用量越来越大，肿瘤病人药物获得率提高，药物价格降低，最终病人受益于国家医保谈判的政策实施。 |
| 英文摘要: |
| Objective To analyze the clinical application of new antineoplastic drugs priced by medical insurance price negotiationand used in a tertiary chest hospital, and to provide reference for standardizing their rational utilization and policy optimization.Meth- ods Annual consumption sum, medication frequency (DDDs), average daily cost (DDC), the ranking ratio (B/A), clinical rationalityand quality control indexes of new antineoplastic drugs priced by medical insurance price negotiation and used in Anhui Chest Hospitalfrom March 2020 to February 2023 were analyzed statistically.Results The sales amount of new antineoplastic drugs accounted for12.55%, 16.33% and 15.84% respectively of total drug amount from 2020 to 2022, among which the proportion of macromolecularmonoclonal antibody drugs increased year by year, accounting for 3.28%, 5.52% and 6.76%. The total DDDs increased by 72.24% in2021 compared with 2020, and 26.26% in 2022 compared with 2021. DDDs of newly added drugs negotiated in 2020 had a particularlygreat increase, among which tislelizumab (17 162.50%) had the greatest increase. The proportion of drugs with DDC decreased year byyear was 63.16%. Drugs with B/A≥1 each year accounted for more than 65.00%. The proportion of DDDs of domestic drugs of macromo-lecular monoclonal antibody was increasing. The rationality rate of new antineoplastic drugs was increasing year by year. The number ofadverse reactions was more than 50 cases in the past two years, and the extended clinical application of drugs was less. The pathologi-cal diagnosis and detection rate of patients using new antineoplastic drugs in the past three years was 100.00%, and the utilization rateof restricted antineoplastic drugs increased year by year.Conclusions The use of new antineoplastic drugs priced by medical insur-ance price negotiation is basically reasonable in this hospital. DDDs increased significantly, DDC decreased, and the use of domesticmacromolecular monoclonal antibody was increasing. Drug access rate of cancer patients has increased and drug price has decreased.Patients benefit from the implementation of national medical insurance price negotiation policy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
